{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:26:40Z","timestamp":1791505600203,"version":"4.3.4"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The phase 2 data presented here support the development of TSND-201 for posttraumatic stress disorder (PTSD), a disorder for which there is a significant unmet need for rapid-acting and effective treatments. TSND-201 (methylone) is a highly selective, rapid-acting neuroplastogen that releases serotonin, norepinephrine, and dopamine without direct activity at 5-hydroxytryptamine (5-HT) 2A receptors that has shown rapid, robust, and long-lasting benefit for preclinical PTSD-related behaviors and has been well tolerated in phase 1 studies of healthy volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of TSND-201 vs placebo in adults with PTSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, Participants<\/jats:title>\n                    <jats:p>\n                      A Study to Assess the Use of Methylone in the Treatment of PTSD (IMPACT-1) part B was a phase 2, multicenter, double-blind, placebo-controlled, 10-week randomized clinical trial of TSND-201 in people with PTSD conducted between November 29, 2023, and February 19, 2025, across 16 sites in the US, UK, and Ireland. Adults aged 18 to 65 years who met\n                      <jats:italic>DSM-5<\/jats:italic>\n                      criteria for current PTSD and 6 months or more of symptoms (Clinician-Administered PTSD Scales for\n                      <jats:italic>DSM-5<\/jats:italic>\n                      [CAPS-5]\u2009\u226535) were eligible.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants were randomized 1:1 to receive TSND-201 or placebo. There were 4 once-weekly oral dosing sessions (150 mg followed by 100 mg or placebo). No psychotherapy was provided; however, dosing sessions were monitored by mental health professionals using a nondirective approach. Participants were followed up for 6 weeks after the last dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>\n                      The primary end point was change from baseline to day 64 in the CAPS-5 total severity score. Secondary end points included changes in PTSD Checklist for\n                      <jats:italic>DSM-5<\/jats:italic>\n                      (PCL-5), Sheehan Disability Scale (SDS), and Montgomery-\u00c5sberg Depression Rating Scale (MADRS) scores. Other measures included response (\u226550% improvement from baseline), remission (\u226411 total severity score), loss of PTSD diagnosis, changes in CAPS-5 symptom clusters, and incidence of treatment-emergent adverse events (TEAEs). Safety was assessed by monitoring adverse events, vital signs, and Columbia-Suicide Severity Rating Scale.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 65 participants (mean [SD] age, 43.7 [10.5] years; 39 female [60.0%]), TSND-201 demonstrated significantly greater improvement in CAPS-5 total score than placebo (least-squares mean difference, 9.64; 90% CI, \u221216.48 to \u22122.80;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.01). PCL-5 (\u221228.46 vs \u221219.47; LS mean treatment difference,\u2009\u22128.99; 90% CI, \u221217.81 to \u22120.17), SDS (\u22128.29 vs \u22123.57; LS mean treatment difference,\u2009\u22124.72; 90% CI, \u22128.84 to \u22120.61), and MADRS (\u221213.94 vs \u22127.73; LS mean treatment difference,\u2009\u22126.21; 90% CI, \u221212.41 to \u22120.27) scores were also improved. Common TEAEs in the TSND-201 group included headache, decreased appetite, nausea, dizziness, blood pressure increased, dry mouth, insomnia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Results of this randomized clinical trial reveal that TSND-201 demonstrated statistically significant efficacy and was well tolerated, supporting its potential as a rapid-acting, durable treatment for PTSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05741710\">NCT05741710<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.4625","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:30:37Z","timestamp":1771432237000},"page":"469","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD"],"prefix":"10.1001","volume":"83","author":[{"given":"Amanda","family":"Jones","sequence":"first","affiliation":[{"name":"Transcend Therapeutics, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Warner-Schmidt","sequence":"additional","affiliation":[{"name":"Transcend Therapeutics, New York, New York"},{"name":"Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kwak","sequence":"additional","affiliation":[{"name":"Transcend Therapeutics, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stogniew","sequence":"additional","affiliation":[{"name":"Transcend Therapeutics, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Mandell","sequence":"additional","affiliation":[{"name":"Transcend Therapeutics, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence H.W.","family":"Ching","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray B.","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and School of Public Health, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kelmendi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"yoi250079r1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14116","article-title":"The economic burden of posttraumatic stress disorder in the US from a societal perspective.","volume":"83","author":"Davis","year":"2022","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"yoi250079r2","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1080\/03007995.2021.1978417","article-title":"Prevalence of posttraumatic stress disorder in the US: a systematic literature review.","volume":"37","author":"Schein","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"yoi250079r3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pnpbp.2008.12.004","article-title":"Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review.","volume":"33","author":"Berger","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"yoi250079r4","doi-asserted-by":"publisher","DOI":"10.1080\/20008198.2020.1802920","article-title":"Pharmacological therapy for posttraumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation, and head-to-head approaches.","volume":"12","author":"Hoskins","year":"2021","journal-title":"Eur J Psychotraumatol"},{"issue":"6","key":"yoi250079r5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"yoi250079r6","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat Med"},{"issue":"23","key":"yoi250079r7","doi-asserted-by":"publisher","first-page":"14636","DOI":"10.3390\/ijms232314636","article-title":"Methylone and MDMA pharmacokinetics following controlled administration in humans.","volume":"23","author":"Poyatos","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"yoi250079r8","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3390\/biology10080788","article-title":"A comparison of acute pharmacological effects of methylone and MDMA administration in humans and oral fluid concentrations as biomarkers of exposure.","volume":"10","author":"Poyatos","year":"2021","journal-title":"Biology (Basel)"},{"key":"yoi250079r9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1122861","article-title":"Pharmacological effects of methylone and MDMA in humans.","volume":"14","author":"Poyatos","year":"2023","journal-title":"Front Pharmacol"},{"key":"yoi250079r10","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1353131","article-title":"Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA.","volume":"18","author":"Warner-Schmidt","year":"2024","journal-title":"Front Neurosci"},{"issue":"5","key":"yoi250079r11","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/npp.2011.304","article-title":"The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.","volume":"37","author":"Baumann","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"yoi250079r12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0014-2999(99)00538-5","article-title":"Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines.","volume":"381","author":"Cozzi","year":"1999","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"yoi250079r13","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.bcp.2013.04.004","article-title":"Substituted methcathinones differ in transporter and receptor interactions.","volume":"85","author":"Eshleman","year":"2013","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"yoi250079r14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1177\/0269881119844185","article-title":"Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems.","volume":"33","author":"Luethi","year":"2019","journal-title":"J Psychopharmacol"},{"issue":"2","key":"yoi250079r15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","article-title":"Pharmacological characterization of designer cathinones in vitro.","volume":"168","author":"Simmler","year":"2013","journal-title":"Br J Pharmacol"},{"key":"yoi250079r17","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-025-02206-z","article-title":"Methylone promotes neurite outgrowth and has long-lasting effects on fear extinction learning.","author":"Warner-Schmidt","journal-title":"Neuropsychopharmacology"},{"key":"yoi250079r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109787","article-title":"Methylone produces antidepressant-relevant actions and prosocial effects.","volume":"242","author":"Li","year":"2024","journal-title":"Neuropharmacology"},{"key":"yoi250079r21","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1041277","article-title":"Methylone, a rapid acting entactogen with robust anxiolytic and antidepressantlike activity.","volume":"13","author":"Warner-Schmidt","year":"2023","journal-title":"Front Psychiatry"},{"key":"yoi250079r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2024.111201","article-title":"Methylone regulates fear memory and amygdala activity: a potential treatment for posttraumatic stress disorder?","volume":"136","author":"Chou","year":"2025","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"yoi250079r23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/978-3-031-43005-3","article-title":"Fear extinction learning in posttraumatic stress disorder.","volume":"64","author":"Lokshina","year":"2023","journal-title":"Curr Top Behav Neurosci"},{"issue":"3","key":"yoi250079r24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1037\/pas0000486","article-title":"The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans.","volume":"30","author":"Weathers","year":"2018","journal-title":"Psychol Assess"},{"issue":"12","key":"yoi250079r25","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from 3 multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"4","key":"yoi250079r26","doi-asserted-by":"publisher","DOI":"10.1111\/cpsp.12364","article-title":"Let\u2019s all get on the same page: a commentary on \u201cdefining response and nonresponse to PTSD treatments: a systematic review\u201d.","volume":"27","author":"Larsen","year":"2020","journal-title":"Clin Psychol (New York)"},{"issue":"4","key":"yoi250079r27","article-title":"Defining response and non-response to PTSD treatments: a systematic review.","volume":"27","author":"Varker","year":"2020","journal-title":"Clin Psychol (New York)"},{"key":"yoi250079r28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0079-6123(07)67012-5","article-title":"Structural and functional plasticity of the human brain in posttraumatic stress disorder.","volume":"167","author":"Bremner","year":"2008","journal-title":"Prog Brain Res"},{"issue":"5","key":"yoi250079r30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41582-022-00635-8","article-title":"Posttraumatic stress disorder: clinical and translational neuroscience from cells to circuits.","volume":"18","author":"Ressler","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"yoi250079r31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S2215-0366(17)30015-9","article-title":"How do antidepressants work\u2014new perspectives for refining future treatment approaches.","volume":"4","author":"Harmer","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"yoi250079r32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-023-01666-5","article-title":"Therapeutic mechanisms of psychedelics and entactogens.","volume":"49","author":"Heifets","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"yoi250079r33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11920-017-0829-z","article-title":"Synaptic loss and the pathophysiology of PTSD: implications for ketamine as a prototype novel therapeutic.","volume":"19","author":"Krystal","year":"2017","journal-title":"Curr Psychiatry Rep"},{"issue":"5","key":"yoi250079r34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/jts.21956","article-title":"Prevalence of a positive screen for PTSD among OEF\/OIF and OEF\/OIF-era veterans in a large population-based cohort.","volume":"27","author":"Dursa","year":"2014","journal-title":"J Trauma Stress"},{"issue":"9","key":"yoi250079r35","doi-asserted-by":"publisher","first-page":"966","DOI":"10.7205\/MILMED-D-13-00175","article-title":"The National Health Study for a new generation of US veterans: methods for a large-scale study on the health of recent veterans.","volume":"178","author":"Eber","year":"2013","journal-title":"Mil Med"},{"key":"yoi250079r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2019.102133","article-title":"Examining military population and trauma type as moderators of treatment outcome for first-line psychotherapies for PTSD: a meta-analysis.","volume":"67","author":"Straud","year":"2019","journal-title":"J Anxiety Disord"},{"key":"yoi250079r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101505","article-title":"Assessment of blinding in randomized controlled trials of antidepressants for depressive disorders 2000-2020: a systematic review and meta-analysis.","volume":"50","author":"Lin","year":"2022","journal-title":"EClinicalMedicine"},{"key":"yoi250079r16","author":"Warner-Schmidt","year":"2024"},{"key":"yoi250079r18","author":"Jones","year":"2023"},{"key":"yoi250079r19","author":"Yu","year":"2022"},{"key":"yoi250079r29","first-page":"251","volume-title":"Handbook of PTSD: Science and Practice","author":"Nash","year":"2014","edition":"2nd ed"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2844885\/jamapsychiatry_jones_2026_oi_250079_1777052927.34149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:00:32Z","timestamp":1778079632000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2844885"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.4625","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}